

Evofem Biosciences to Participate in Investor Conferences

SAN DIEGO, Sept. 1, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Sandra Pelletier will present and host one-on-one meetings at two upcoming investor conferences as follows:

| H.C. Wainwright 23rd Annual Global Investment Conference | |
|--|--|
| Format: | Corporate presentation |
| Date: | Monday, September 13, 2021 |
| Time: | 7:00 a.m. ET (4:00 a.m. PT) |
| Morgan Stanley Virtual Global Healthcare Conference | |
| Format: | Fireside chat |
| Date: | Tuesday, September 14, 2021 |
| Time: | 12:30 – 1:00 p.m. ET (9:30 -10:00 a.m. PT) |

Webcasts of both events will be available through the Events section of the Evofem website at <https://evofem.investorroom.com/events> for 30 days.

About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product, [Phexxi®](#) (lactic acid, citric acid and potassium bitartrate), in the United States in September 2020. The Company is evaluating lead product candidate EVO100 for the prevention of urogenital *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infection in women in the ongoing Phase 3 clinical trial, '[EVOGUARD](#).' For more information, please visit evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact

Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

